SecBot SecBot
8-K ·Filed Apr 28, 2026

PTCT

PTC THERAPEUTICS, INC.
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001070081-26-000006
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The positive interim data and Novartis's Phase 3 initiation reduce pipeline risk for PTCT. Traders should monitor regulatory interactions and potential accelerated approval pathways. The data supports a potential disease-modifying therapy for Huntington's disease, a high unmet need.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$64.55
T+0 close · Apr 28, 2026 · via day close
Latest settled
+19.01%
T+60 · $76.82
Vs SPY
+14.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $64.55entry
  2. T+1 · 7mo ago +0.79%α −0.23% · $65.06
  3. T+5 · 7mo ago +3.13%α +0.02% · $66.57
  4. T+20 · 6mo ago +10.07%α +4.02% · $71.05
  5. T+60 · 4mo ago +19.01%α +14.90% · $76.82

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PTC Therapeutics reported positive 24-month interim data from the PIVOT-HD extension study of votoplam in Huntington's disease, showing a 52% dose-dependent slowing of disease progression at 10 mg in Stage 2 patients versus a matched natural history cohort. Novartis has initiated the global Phase 3 INVEST-HD study, which de-risks development costs for PTC.

Key Facts

  • PIVOT-HD 24-month interim analysis showed 52% slowing on cUHDRS for 10 mg votoplam vs natural history in Stage 2 HD patients
  • 5 mg dose showed 28% slowing on cUHDRS vs natural history
  • No treatment-related NfL increases; mean NfL below baseline at 24 months
  • Novartis initiated global Phase 3 INVEST-HD study enrolling ~770 patients, sponsored and funded by Novartis
  • Safety profile remained favorable with no new safety signals at 24 months

Financial Impact

Not specified

Risk Factors

  • Phase 3 INVEST-HD may fail to replicate efficacy or show unexpected safety issues
  • Competition from other HD-targeting therapies could limit market potential
  • Regulatory timeline and approval uncertainty remain

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001070081-26-000006
Document: tmb-20260428xex99d1.htm0001070081-26-000006
Document: tmb-20260428xex99d2.htm0001070081-26-000006
Document: 0001070081-26-000006-index-headers.html0001070081-26-000006
Document: 0001070081-26-000006-index.html0001070081-26-000006
Document: 0001070081-26-000006.txt0001070081-26-000006

Track record

29 reports on PTCT

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +9.12% at T+5 after the Oct 29, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  7. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
  9. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
  10. Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026